Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




World's Highest-Multiplex POC System with RNA Quantitating Ability Detects Bacterial Infection

By LabMedica International staff writers
Posted on 20 Nov 2023

Sepsis and antimicrobial resistance (AMR) are major contributors to increasing deaths and healthcare costs globally. More...

In clinical settings, diagnosing and treating these conditions present significant challenges. Physicians, especially in emergency rooms, often face difficulties in making prompt, accurate decisions regarding antibiotic use for the roughly 15 million patients annually who present with suspected acute infection and sepsis. In response to this challenge, a new test system specifically designed for emergency department use is being developed. This system aims to evaluate the likelihood of bacterial or viral infections and the risk of acute decompensation, which necessitates ICU-level care, in patients with suspected acute infection and sepsis.

Inflammatix, Inc. (Sunnyvale, CA, USA) has completed technical development for its TriVerity Acute Infection and Sepsis Test System. This system includes the Myrna Instrument and the TriVerity Cartridge. The Myrna Instrument is adept at analyzing up to 64 messenger RNAs (mRNAs) from whole blood or other types of samples within approximately 30 minutes. Designed for potential use at the point-of-care, the Myrna Instrument is aimed to meet the criteria for Clinical Laboratory Improvement Amendments (CLIA) waiver. The accompanying disposable cartridges are designed to be stable at room temperature for up to a year.

The TriVerity Acute Infection and Sepsis Test, a leading product from Inflammatix, utilizes a panel of 29 mRNAs to interpret the body's immune response, assisting in the diagnosis of patients with suspected acute infection and sepsis. This test is particularly targeted at diagnosing patients who present with suspected infections in U.S. emergency departments. Inflammatix is actively working on completing its clinical studies, including the SEPSIS-SHIELD study, which is essential for the submission of the TriVerity Test system to the U.S. Food and Drug Administration (FDA). This multi-center study has already enrolled 955 patients out of the anticipated 1,500. Inflammatix anticipates the completion of the study and the subsequent FDA submission by spring 2024.

"Myrna will be the world's highest-multiplex point-of-care system capable of quantitating RNA, allowing us to bring 'precision medicine' into acute care settings," said Dr. Timothy Sweeney, CEO and co-founder of Inflammatix. "Completing technical development brings TriVerity a step closer to FDA submission and launch, and enables us to execute key clinical studies."

"With the completion of the test system, we look forward to further exploring partnerships that bring existing RNA signatures onto the Myrna ecosystem," Dr. Sweeney commented. "This may be an especially viable pathway given expected changes to the regulation of lab-developed tests and the increased reliance on a biomarker-driven approach to immunotherapy development."

Related Links:
Inflammatix, Inc.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Collection and Transport System
PurSafe Plus®
New
Blood Glucose Test Strip
AutoSense Test
New
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The study highlights the potential of cCAFs as a biomarker for early diagnosis and prognosis (H J Woo et al., Analytical Chemistry (2025). DOI: 10.1021/acs.analchem.5c02154)

Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy

Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.